LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "aggressive large" as a keyword



Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B‐Cell Lymphoma

Sign Up to like & get
recommendations! Published in 2024 at "American Journal of Hematology"

DOI: 10.1002/ajh.27548

Abstract: Chimeric antigen receptor (CAR) T‐cell therapy has revolutionized treatment of aggressive large B‐cell lymphoma (aLBCL). Patients with transformed indolent non‐Hodgkin lymphoma (tiNHL) were included in key CAR trials, but outcomes of CAR for this distinct,… read more here.

Keywords: car; large cell; lymphoma; aggressive large ... See more keywords

Aggressive large B‐cell lymphoma triggered by a parvovirus B19 infection in a previously healthy child

Sign Up to like & get
recommendations! Published in 2019 at "Hematological Oncology"

DOI: 10.1002/hon.2665

Abstract: In absence of red blood cells disease or immune defect, parvovirus B19 (PVB‐19) is usually considered as a benign condition. Here, we report the case of a 10‐year‐old boy, previously healthy, presenting with a PVB‐19… read more here.

Keywords: aggressive large; previously healthy; large cell; cell ... See more keywords

Defining and Addressing the Current Unmet Medical Needs for the Frontline Treatment of Advanced Stage Aggressive Large B‐Cell Lymphoma: A Perspective From an Ad Hoc Panel of Italian Experts

Sign Up to like & get
recommendations! Published in 2025 at "Hematological Oncology"

DOI: 10.1002/hon.70152

Abstract: Aggressive large B‐cell lymphomas (LBCL) include a range of disease types characterized by heterogenous histopathologic, molecular, and genetic features. In this review, we summarize the main standardized disease assessments, treatments and patient journey and we… read more here.

Keywords: panel; treatment; advanced stage; large cell ... See more keywords
Photo by nci from unsplash

Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL): Updated results from the PILOT study.

Sign Up to like & get
recommendations! Published in 2020 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2020.38.15_suppl.8040

Abstract: 8040Background: Patients (pts) with aggressive large B-cell NHL who are R/R after first-line immunochemotherapy and not eligible for high-dose chemotherapy and HSCT have a poor prognosis and no est... read more here.

Keywords: lisocabtagene maraleucel; aggressive large; line; maraleucel liso ... See more keywords